123I-iodobenzamide-SPECT Predicts Dopaminergic Responsiveness in patients with De Dovo Parkinsonism
Neurol 42:556-561, Schwarz,J.,et al, 1992
Long-Term Effectivenss of Dopamine Agonists and Monoamine Oxidase B Inhibitors Compared with Levodopa as Initial Treatment for Parkinsons Disease (PD MED): A Large, Open-Label, Pragmatic Randomised Trial
Lancet 383: Doi: 10.1016/S0140-6736, PD MED Collaborative Group, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Othello Syndrome in Parkinson Disease Patients Without Dementia
The Neurologist 15:34-36, Cannas,A.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease
Arch Neurol 65:1604-1611, Cilia,R.,et al, 2008
Levodopa for the Treatment of Parkinsons Disease
NEJM 359:2468-2476, LeWitt,P.A., 2008
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Ropinirole 24-Hour Prolonged Release: Randomized, Controlled Study in Advanced Parkinson Disease
Neurol 68:1108-1115, Pahwa,R.,et al, 2007
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Restless Legs Syndrome
NEJM 348:2103-2109, Earley,C.J., 2003
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Ten-year Follow-up of Three Different Initial Treatments in De-novo PD
Neurol 57:1687-1694, Lees,A.J.,et al, 2001
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000
Cabergoline Treatment of Early Parkinson's Disease:First Yr of Trtm Comparison of Cabergoline & Levodopa
Neurol 48:363-368, Rinne,U.K.,et al, 1997
Restless Legs Syndrome:Clinicoetiologic Correlates
Neurol 47:1435-1441, Ondo,W.&Jankovic,J., 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Reverse Shapiro's Syndrome:Hirayama
K. , et al, Arch Neurol 51:494-49694., , 1994
A Multicenter Double-Blind Placebo-Controlled Trial of Pergolide as an Adjunct to Sinemet in Parkinson's Disease
Movement Disorders, 9:40-471994., Olanow,C.W.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Comparisons of Therapeutic Effects of Levodopa
Levodopa & Selegiline, & Bromocriptine in Pts with Early, Mild Parkinson's, Parkinson's Res Grp in U, , BMJ 372,1993., 1993
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Lisuride, A Dopamine Agonist in the Treatment of Early Parkinson's Disease
Neurol 39:336-339, Rinne,U.K., 1989
International Symposium on Early Dopamine Agonist Therapy of Parkinson's Disease
Arch Neurol 45:204-208, Kurlan,R., 1988
Early Combination of Bromocriptine & Levodopa in the Treatment of Parkinson's Disease:A 5-Year Follow-up
Neurol 37:826-828, Rinne,U.K., 1987
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Low Dosages of Bromocriptine Added to Levodopa in Parkinson's Disease
Neurol 35:199-206, Maier,M.M.,et al, 1985
Bromocriptine in Parkinson Disease:Further Studies
Neurol 29:363-369, Lieberman,A.N.,et al, 1979
Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978
Successful Use of Bromocriptine in the treatment of a Patient with Chronic Portasystemic Encephalopathy
NEJM 296:793, Morgan,M.Y.,et al, 1977
Developments in the Treatment of Parkinsonism
NEJM 295:1433, Calne,D.B., 1976
Studies with Bromocriptine Part 2. Double-blind Comparison with Levodopa in Idiopathic Parkinsonism
Neurol 26:511, Kartzinel,R.,et al, 1976
Treatment of Parkinson's Disease with Bromocriptine
NEJM 295:1400, Lieberman,A.,et al, 1976
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Dopa-Responsive Dystonia:Pathological and Biochemical Observations in a Case
Ann Neurol 35:396-402, 3811994., Rajput,A.H.,et al, 1994
Neuroleptic Malignant Synd in Parkinson's after Withdrawal or Alteration of Dopaminergic Therapy
Arch Int Med 151:794-796, Keyser,D.L.&Rodnitzky,R.L., 1991
Huntington's Chorea-Deficiency of Y-Aminobutynic Acid in Brain
NEJM 288:337, 1973, 289:104, 1973, 292:10295., Perry,T.,et al, 1975
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975
Drug Therapy of Parkinsonism
NEJM 287:20, Yahr,M.,et al, 1972
Implications of Amphetamine-Induced Stereotyped Behavior as a Model for Tardive Dyskinesias
Arch Gen Psychiat 27:502-507, Rubovits,R.,et al, 1972